Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy

Multiple primary lung cancer (MPLC) remains a tough challenge to diagnose and treat. Although neoadjuvant immunotherapy has shown promising results in early stage non-small cell lung cancer, whether such modality can benefit all primary lesions remains unclear. Herein, we performed integrated multio...

Full description

Saved in:

Bibliographic Details
Published in:	Journal for immunotherapy of cancer Vol. 9; no. 4; p. e002312
Main Authors:	Zhang, Chao, Yin, Kai, Liu, Si-Yang, Yan, Li-Xu, Su, Jian, Wu, Yi-Long, Zhang, Xu-Chao, Zhong, Wen-Zhao, Yang, Xue-Ning
Format:	Journal Article
Language:	English
Published:	England BMJ Publishing Group LTD 01-04-2021 BMJ Publishing Group
Subjects:	Adenocarcinoma of Lung - drug therapy Adenocarcinoma of Lung - genetics Adenocarcinoma of Lung - immunology Aged Antibodies, Monoclonal, Humanized - therapeutic use Antigens Cancer Case Report Cell growth Chemotherapy, Adjuvant Fatty acids Female Gene expression Gene Expression Profiling Gene Expression Regulation, Neoplastic Genomics Humans Hypoxia Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Ligands Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - immunology Lymphocytes Metabolism Metastasis Multiple Pulmonary Nodules - drug therapy Multiple Pulmonary Nodules - genetics Multiple Pulmonary Nodules - immunology Mutation Neoadjuvant Therapy Neoplasms, Multiple Primary - drug therapy Neoplasms, Multiple Primary - genetics Neoplasms, Multiple Primary - immunology RNA-Seq T cell receptors Time Factors Transcriptome Treatment Outcome Tumor Microenvironment - immunology translational medical research tumor microenvironment lung neoplasms tumor biomarkers immunotherapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!